Innovative drugs led the gains during the session, and the innovative drug Shanghai-Shenzhen-Hong Kong ETF (517110) rose by more than 1.3%
February 5, 2025
Source: drugdu
35
Innovative drugs led the gains during the session, and the innovative drug Shanghai-Shenzhen-Hong Kong ETF (517110) rose by more than 1.3%.
Galaxy Securities said that the pharmaceutical sector has undergone a long period of adjustment, the overall valuation is at a low level, and the public offering positions are underweight. In 2025, under the policy background of supporting and guiding the development of commercial insurance, the payment side is expected to improve marginally, and innovative drugs and equipment are expected to benefit. The pharmaceutical market will usher in a recovery, and structural opportunities still exist. From the perspective of short-term and medium- and long-term deterministic growth, targets are selected, and innovative drugs and industrial chains are optimistic about the continued good performance this year.
Investors without stock accounts can seize investment opportunities in innovative drugs through the link fund (014118) of the innovative drug Shanghai-Shenzhen-Hong Kong ETF.
Source: https://finance.eastmoney.com/
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Haisike has been approved to conduct clinical trials of the innovative drug HSK39004 February 7, 2025
- Innovative drugs are expected to accelerate into hospitals, and the Class C medical insurance catalogue is about to be released February 7, 2025
- Keytruda sold $29.5 billion last year, and Merck suspended shipments of HPV vaccines to the Chinese market February 7, 2025
- The application for marketing authorization of the independently developed drug of the holding subsidiary was approved by the EU February 7, 2025
- Nepal launches national HPV vaccination program, expected to benefit more than 1.68 million girls February 6, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
